A phase Ib trial assessing the safety and efficacy of autologous expanded T regulatory cell therapy for the treatment of Crohn's disease
Latest Information Update: 26 May 2020
At a glance
- Drugs TRK 001 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 26 May 2020 According to a Tract Therapeutics pipeline, this FDA-approved trial in a single site was scheduled for October 2019.
- 26 May 2020 New trial record